Nyrada Talks PreClinical Success with 180 Markets, page-91

all you really have to compare it to is AGN at a 70 million market cap before GLP and phase 1 studies in 2021, NYR is a more effective treatment with no need of combining it with thrombotics and a single therapy and not a dual therapy which is already proven to work

Current market cap is 22 million with 5 million in cash and 3-4 million in rebates coming after July 1st. Got a significant rerate to go as it was at 40 cents last time without it being proven and this current results exceeded modelling so previous highs will be tested short term